uploads/2017/06/Imbruvica-Revenues-1.png

Imbruvica May Witness Significant Revenue Growth in 2017

By

Updated

Imbruvica’s revenue trend

In 1Q17, AbbVie’s (ABBV) Imbruvica generated revenue of $551 million, which reflected a ~44.7% year-over-year (or YoY) revenue rise and a 7.8% quarter-over-quarter rise.

The drug’s entry as a first-line treatment for chronic lymphocytic leukemia (or CLL) has been a key revenue driver.

In 2016, Imbruvica generated revenue of ~$1.8 billion. In 1Q17, the company estimated that over 21% of new CLL patients were starting Imbruvica as their frontline CLL therapy. AbbVie has projected net revenue from Imbruvica of more than $2.4 billion in 2017. The drug’s rising sales may boost the share price of the Health Care Select Sector SPDR ETF (XLV). AbbVie makes up ~3.7% of XLV’s total portfolio holdings.

The above graph represents Imbruvica’s revenue trajectory from 1Q16 to 1Q17. To know more about Imbruvica’s sales, read AbbVie’s Imbruvica Saw Solid Demand in 1Q17.

Article continues below advertisement

About Imbruvica

Imbruvica (ibrutinib), a kinase inhibitor, is indicated for the treatment of mantle cell lymphoma (or MCL) patients who have received one prior therapy.

In March 2016, Imbruvica received FDA approval as a first-line therapy for patients with CLL. In its Phase 3 RESONATE-2 trial, the drug proved efficacious in treatment-naïve CLL patients compared to traditional chemotherapy. Imbruvica is a non-chemotherapy drug in the CLL space.

In June 2016, the FDA designated Imbruvica as a breakthrough therapy for chronic graft versus host disease patients who’d failed to respond to one or more prior systemic therapies. In January 2017, Imbruvica received FDA approval for relapsed/refractory marginal zone lymphoma (or MZL).

AbbVie faces tough competition in the oncology market from the likes of Celgene (CELG), Amgen (AMGN), Novartis (NVS), and other biosimilar manufacturers.

In the next article, we’ll discuss various ongoing clinical trials for Imbruvica and Venclexta in greater detail.

Advertisement

More From Market Realist